Table 4.

Parameters of the cross‐sectional linear model predicting baseline outcome score using single‐protein models consisting of baseline biomarker protein concentration, age, sex, and BMI that passed the p = 0.05 significance threshold.

Endpoint	Biomarker	Estimate	R‐squared	p‐value
DGMV	FLRT2	−0.008	0.16	0.035
	GFAP	−0.015	0.19	<0.001*
	MOG	0.008	0.15	0.037
GMV	CCL20	−0.006	0.25	0.016
	GFAP	−0.009	0.33	<0.001*
	FLRT2	−0.005	0.25	0.036
LVV	MOG	−0.028	0.19	0.024
	GFAP	0.060	0.26	<0.001*
Thalamus	MOG	0.011	0.17	0.008
	GFAP	−0.016	0.18	0.001*
	FLRT2	−0.008	0.16	0.043
WMV	GFAP	−0.008	0.1	0.006
	CD6	0.005	0.1	0.048
WBV	GFAP	−0.009	0.29	<0.001*
	FLRT2	−0.004	0.25	0.021
EDSS	PRTG	−0.034	0.23	0.023
	GFAP	0.050	0.24	0.002*
	CD6	−0.034	0.23	0.018
9HPT	PRTG	−0.037	0.25	0.043
PASAT	GFAP	−0.092	0.11	0.022
	APLP1	−0.079	0.09	0.038
SDMT	GFAP	−0.055	0.18	0.013
T25FWT	CXCL13	0.074	0.17	0.017

Refer to Table S8 for the list of protein abbreviations. p‐values smaller than 0.05 were considered significant and those with asterisks (*) survived the Benjamini–Hochberg correction for false discovery rate (FDR).

DGMV, deep gray matter volume; EDSS, Expanded Disability Status Scale; GMV, gray matter volume; LVV, lateral ventricular volume; PASAT, Paced Auditory Serial Addition Test; SDMT, Symbol Digit Modalities Test; T25FWT, Timed 25‐Foot Walk Test; WMV, white matter volume; WBV, whole brain volume; 9HPT, 9‐Hole Peg Test.